Combination vaccine

Patent metadata

Field	Value
Publication number	US-12337031-B2
Application number	US-202217590173-A
Country	US
Kind code	B2
Filing date	Feb 1, 2022
Priority date	Aug 21, 2013
Publication date	Jun 24, 2025
Grant date	Jun 24, 2025

Abstract

The present invention relates to a vaccine, especially a combination vaccine providing at least a first and a second antigenic function, the combination vaccine comprising at least one RNA encoding at least one or more proteins or fragments, variants or derivatives of proteins awarding antigenic function, wherein the first antigenic function being a Fusion (F) protein or a fragment, variant or derivative of a Fusion (F) protein derived from the virus family Paramyxoviridae and the second antigenic function being an Hemagglutinin (HA) protein or a fragment, variant or derivative of an Hemagglutinin (HA) protein derived from the virus family Orthomyxoviridae. Furthermore, the present invention is directed to a kit or kit of parts comprising the components of said combination vaccine and to said combination vaccine for use in a method of prophylactic or therapeutic treatment of diseases, particularly in the prevention or treatment of infectious diseases like RSV and influenza.

First claim

The invention claimed is:

1. A cytotoxic T cell-inducing immunogenic composition comprising:
i) at least a first mRNA comprising a protein coding sequence encoding at least the extracellular domain of a human respiratory syncytial virus (RSV) Fusion protein (F) antigen, said RSV-F antigen comprising an amino acid sequence encoding the T-cell epitopes of SEQ ID NOs: 24, 25 and 26; and
ii) at least a second mRNA comprising a protein coding sequence encoding at least the extracellular domain of a human influenza virus Hemagglutinin (HA) protein.

2. The immunogenic composition of claim 1 , wherein the first and second mRNAs comprise 5′ Cap structures.

3. The immunogenic composition of claim 2 , wherein the first and second mRNAs comprise poly-A sequence of about 50 to about 250 adenosine nucleotides.

4. The immunogenic composition of claim 3 , wherein the first and second mRNAs comprise 5′ and/or 3′ UTR sequences.

5. The immunogenic composition of claim 4 , wherein the protein coding sequence of the first and second mRNAs is modified to increase the G/C content.

6. The immunogenic composition of claim 4 , wherein the first and second mRNAs are complexed with a cationic or polycationic compound.

7. The immunogenic composition of claim 6 , wherein the first and second mRNAs are complexed with a cationic or polycationic protein.

8. The immunogenic composition of claim 6 , wherein the first and second mRNAs are complexed with a cationic lipid.

9. The immunogenic composition of claim 4 , wherein the HA protein is a full-length HA protein.

10. The immunogenic composition of claim 4 , wherein the F protein is a full-length HA protein.

11. The immunogenic composition of claim 4 , wherein the HA protein is an Influenza A HA protein.

12. The immunogenic composition of claim 11 , wherein the Influenza A HA protein is from H1N1, H1N2, H3N1, H3N2, H3N8, H5N1, H5N2, H5N3, H5N8, H5N9, H7N1, H7N2, H7N3, H7N4, H7N7, H9N1, H9N2 or H10N7 Influenza.

13. The immunogenic composition of claim 12 , wherein the Influenza A HA protein is H1 HA protein.

14. The immunogenic composition of claim 4 , wherein the HA protein is an Influenza B HA protein.

15. The immunogenic composition of claim 4 , wherein the composition comprises a further mRNA encoding a further antigen.

16. The immunogenic composition of claim 15 , wherein the further antigen is an Influenza HA protein.

17. The immunogenic composition of claim 5 , wherein the first and second mRNAs are complexed with a cationic lipid.

18. The immunogenic composition of claim 17 , wherein the HA protein is an Influenza A HA protein.

19. The immunogenic composition of claim 18 , wherein the HA protein is a full-length HA protein.

20. The immunogenic composition of claim 17 , wherein the first mRNA encodes a RSV F protein comprising least the extracellular domain and the transmembrane domain of the RSV F protein.

21. The immunogenic composition of claim 4 , wherein the HA protein is from a H1N1 virus.

22. The immunogenic composition of claim 21 , wherein upon intradermal or intramuscular injection to a mammal the composition induces a cytotoxic T cell response to the amino acid epitope of SEQ ID NOs: 24, 25 and/or 26.

23. The immunogenic composition of claim 22 , wherein upon intradermal or intramuscular injection to a mammal the composition induces a cytotoxic T cell response to the amino acid epitope of SEQ ID NO: 24.

24. The immunogenic composition of claim 22 , wherein the first and second mRNAs are complexed with a cationic or polycationic compound.

Assignees

• Curevac Ag
• CureVac SE

Inventors

• Kallen Karl-Josef
• Kramps Thomas
• Schnee Margit
• Voss Daniel

Classifications

• C12N2760/18534

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2760/16134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• C07K14/005

  from viruses · CPC title

• A61K2039/575

  humoral response · CPC title